CBRX Share Price

Open 7.47 Change Price %
High 7.70 1 Day 0.10 1.33
Low 7.47 1 Week 0.26 3.53
Close 7.62 1 Month 0.26 3.53
Volume 30540 1 Year 0.26 3.53
52 Week High 175.04
52 Week Low 141.75
CBRX Important Levels
Resistance 2 7.83
Resistance 1 7.75
Pivot 7.60
Support 1 7.49
Support 2 7.41
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%

Columbia Laboratories, Inc. (NASDAQ: CBRX)

CBRX Technical Analysis 5
As on 13th Mar 2015 CBRX Share Price closed @ 7.62 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 6.16 & Strong Buy for SHORT-TERM with Stoploss of 6.35 we also expect STOCK to react on Following IMPORTANT LEVELS.
CBRX Target for May
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
CBRX Other Details
Segment EQ
Market Capital 54175788.00
Sector Healthcare
Industry Drug Delivery
Offical website http://www.columbialabs.com
CBRX Address
4 Liberty Square
Fourth Floor
Boston, MA 02109
United States
Phone: 617-639-1500
Fax: 617-482-0618
CBRX Latest News
Interactive Technical Analysis Chart Columbia Laboratories, Inc. ( CBRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Columbia Laboratories, Inc.
CBRX Business Profile
Columbia Laboratories, Inc. (Columbia), incorporated in 1986, is engaged in the business of developing, manufacturing and selling pharmaceutical products that utilize its bioadhesive drug delivery technologies to treat various medical conditions. As of December 31, 2011, Columbia developed and brought to market five bioadhesive vaginal gel products that provide solutions for infertility, pregnancy support, amenorrhea and other gynecologic conditions. All of the products Columbia has developed utilize its bioadhesive delivery system (BDS), which consists principally of a polymer (polycarbophil) and an active ingredient. The Company’s Progesterone products include CRINONE and PROCHIEVE. Its CRINONE and PROCHIEVE vaginal gel products are manufactured in bulk by Fleet Laboratories Limited, Watford, Herts, United Kingdom (Fleet) and filled into overwrapped single-use disposable applicators by Maropack AG, Zell, Switzerland (Maropack). The Company’s CRINONE is a sustained release gel that delivers natural progesterone vaginally. CRINONE utilizes the Company’s BDS, which enables the progesterone to achieve a preferential uptake of drug from the vagina to the uterus, or a first uterine pass effect. The product is available in both 4% and 8% concentrations and in the United States is also known under the trade name PROCHIEVE. CRINONE in both the 8% and 4% concentrations is approved in the United States for the treatment of secondary amenorrhea (loss of menstrual period). Outside the United States, CRINONE has been approved for marketing for one or more medical indications in over 60 countries. CRINONE is sold outside the United States by Merck Serono under a worldwide (excluding the United States) license from the Company. CRINONE is contraindicated in the United States in patients with active thrombophlebitis or thromboembolic disorders, or a history of hormone-associated thrombophlebitis or thromboembolic disorders, missed abortion, undiagnosed vaginal bleeding, liver dysfunction or disease and known or suspected malignancy of the breast or genital organs.